Gravitate Health FHIR Implementation Guide, published by Gravitate Health Project. This guide is not an authorized publication; it is the continuous build for version 0.1.0 built by the FHIR (HL7® FHIR® Standard) CI Build. This version is based on the current content of https://github.com/joofio/test-epi-composition/ and changes regularly. See the Directory of published versions
Full name:
Authorised dose form:
Legal status of supply:
Domain:
Resource status:
Product classification:
Document Details
Generated Narrative: Bundle TEST PURPOSES ONLY - fluad
Language: en
Profile: Bundle - ePI
Final Document at 2022-02-16 13:28:17+0000 by Organization ACME industry for Bundle: identifier = http://ema.europa.eu/identifier#None; type = document; timestamp = 2023-06-27 10:09:22+0000
Document Subject
Generated Narrative: MedicinalProductDefinition mp2551c286e23d3921dbfab879452cee74
identifier: http://ema.europa.eu/identifier
/EU/1/20/1433/001
type: Medicinal Product
domain: Human use
status: active
legalStatusOfSupply: Medicinal product subject to medical prescription
name
productName: Fluad Tetra, suspension for injection in pre-filled syringe
type: Full name
part
part: nan
type: Invented name part
part
part: nan
type: Scientific name part
part
part: nan
type: Strength part
part
part: nan
type: Pharmaceutical dose form part
Usages
Country Jurisdiction Language EU EU en
Document Content
Generated Narrative: Composition composition-en-2551c286e23d3921dbfab879452cee74
Language: en
Profile: Composition (ePI)
identifier: http://ema.europa.eu/identifier
/EU/1/20/1433/001
status: Final
type: Package Leaflet
category: Raw
date: 2022-02-16 13:28:17+0000
author: Organization ACME industry
title: TEST PURPOSES ONLY - fluad
Mode | Time |
Official | 2022-02-16 13:28:17+0000 |
What is in this leaflet
Fluad Tetra is a vaccine against flu (influenza).
When a person is given the vaccine, the immune system (the body s natural defence system) will produce its own protection against the influenza virus. None of the ingredients in the vaccine can cause flu.
Fluad Tetra is used to prevent flu in adults 50 years of age and older.
The vaccine targets four strains of influenza virus following the recommendations by the World Health Organisation for the 2023/2024 season.
You should not receive Fluad Tetra
Warnings and precautions
Talk to your doctor, pharmacist or nurse before receiving Fluad Tetra.
BEFORE receiving the vaccine
As with all vaccines, Fluad Tetra may not fully protect all persons who are vaccinated.
Children Fluad Tetra is not recommended for use in children.
Other medicines and Fluad Tetra Tell your doctor or nurse if you are using, have recently used or might use any other medicines, including medicines obtained without a prescription or if you have recently received any other vaccine.
Pregnancy and breast-feeding
This vaccine is for use in adults 50 years and older. It is not to be used in women who are, or may be, pregnant or breast-feeding.
Driving and using machines Fluad Tetra has no or negligible influence on the ability to drive and use machines.
Fluad Tetra contains potassium and sodium
This vaccine contains less than 1 mmol sodium (23 mg) per dose, i.e. essentially sodium free . This vaccine contains potassium, less than 1 mmol (39 mg) per dose, i.e. essentially potassium free .
Fluad Tetra is given by your doctor or nurse as an injection into the muscle at the top of the upper arm (deltoid muscle).
Adults 50 years of age and older:
One dose of 0.5 ml
Like all medicines, this medicine can cause side effects, although not everybody gets them.
Tell your doctor immediately or go to the casualty department at your nearest hospital if you experience the following serious side effect you may need urgent medical attention or hospitalisation:
Difficulty in breathing, dizziness, a weak and rapid pulse and skin rash which are symptoms of an anaphylactic reaction (a very severe allergic reaction)
The following side effects have been reported during clinical trials in adults 50 years of age and older.
Very common (may affect more than 1 in 10 people):
Common (may affect up to 1 in 10 people):
Uncommon (may affect up to 1 in 100 people):
Most side effects were mild or moderate and went away within 3 days of appearing.
Next to the above side effects, the following side effects occurred occasionally during general use of Fluad Tetra or a similar vaccine in elderly individuals 65 years of age and older.
Reporting of side effects If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via the national reporting system listed in Appendix V. By reporting side effects you can help provide more information on the safety of this medicine.
Keep this medicine out of the sight and reach of children.
Store in a refrigerator (2 C to 8 C). Do not freeze. Discard if the vaccine has been frozen. Keep the pre-filled syringe in the outer carton in order to protect from light.
Do not use this medicine after the expiry date which is stated on the label and carton after EXP. The expiry date refers to the last day of that month.
Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.
What Fluad Tetra contains
per 0.5 ml dose A/Victoria/4897/2022 (H1N1)pdm09-like strain
(A/Victoria/4897/2022 IVR-238) 15 micrograms HA** A/Darwin/9/2021 (H3N2)-like strain
(A/Darwin/6/2021 IVR-227) 15 micrograms HA** B/Austria/1359417/2021-like strain (B/Austria/1359417/2021 BVR-26) 15 micrograms HA** B/Phuket/3073/2013-like strain (B/Phuket/3073/2013 BVR 1B) 15 micrograms HA** *propagated in fertilised hens eggs from healthy chicken flocks and adjuvanted with MF59C.1 **haemagglutinin
This vaccine complies with the WHO recommendations (Northern Hemisphere) and EU recommendation for the 2023/2024 season.
MF59C.1 is included in this vaccine as an adjuvant. Adjuvants are substances included in certain vaccines to accelerate, improve and/or prolong the protective effects of the vaccine. MF59C.1 is an adjuvant that contains per 0.5 ml dose: squalene (9.75 mg), polysorbate (1.175 mg), sorbitan trioleate (1.175 mg), sodium citrate (0.66 mg) and citric acid (0.04 mg).
The other ingredients are sodium chloride, potassium chloride, potassium dihydrogen phosphate, disodium phosphate dihydrate, magnesium chloride hexahydrate, calcium chloride dihydrate and water for injections.
What Fluad Tetra looks like and contents of the pack Fluad Tetra is a suspension for injection in a pre-filled syringe. Fluad Tetra is a milky-white suspension. A single syringe contains 0.5 ml of suspension for injection. Fluad Tetra is available in packs containing 1 or 10 pre-filled syringes with or without needles.
Not all pack sizes may be marketed.
Marketing Authorisation Holder and Manufacturer Seqirus Netherlands B.V. Paasheuvelweg 28,1105 BJ Amsterdam, Netherlands
For any information about this medicine, please contact the local representative of the Marketing Authorisation Holder: Belgi /Belgique/Belgien Seqirus Netherlands B.V.Nederland/Netherlands Tel: +31 (0) 20 204 6
Seqirus Netherlands B.V.
.: +31 (0) 20 204 6 esk republika Seqirus Netherlands B.V. Nizozemsko Tel: +31 (0) 20 204 6Danmark Seqirus Netherlands B.V. Holland Tlf: +31 (0) 20 204 6Deutschland Seqirus GmbH Marburg Tel: 0800/3601Eesti Seqirus Netherlands B.V. Holland Tel: +31 (0) 20 204 6
WIN MEDICA . . : 210 7488Espa a Seqirus Spain, S.L., Barcelona Tel: 937 817 France Seqirus Netherlands B.V. Netherlands T l: +31 (0) 20 204 6Hrvatska Seqirus Netherlands B.V. Nizozemska Tel: +31 (0) 20 204 6Ireland Seqirus UK Limited Maidenhead Tel: +44 1628 641 sland Seqirus Netherlands B.V. Holland S mi: +31 (0) 20 204 6Italia Seqirus S.r.l. Siena Tel: +39 0577 096
Seqirus Netherlands B.V.
: +31 (0) 20 204 6Lietuva Seqirus Netherlands B.V. Nyderlandai Tel: +31 (0) 20 204 6Luxembourg/Luxemburg Seqirus Netherlands B.V. Netherlands T l/Tel: +31 (0) 20 204 6Magyarorsz g Seqirus Netherlands B.V. Hollandia Tel.: +31 (0) 20 204 6Malta Seqirus Netherlands B.V. In-Netherlands Tel: +31 (0) 20 204 6Nederland Seqirus Netherlands B.V. Amsterdam Tel: +31 (0) 20 204 6Norge Seqirus Netherlands B.V. Nederland Tlf: +31 (0) 20 204 6 sterreich Valneva Austria GmbH, Wien Tel: +43 1 20620 2Polska Seqirus Netherlands B.V. Holandia Tel.: +31 (0) 20 204 6Portugal Seqirus Netherlands B.V. Pa ses Baixos Tel: +31 (0) 20 204 6Rom nia Seqirus Netherlands B.V. Olanda Tel: +31 (0) 20 204 6Slovenija Seqirus Netherlands B.V. Nizozemska Tel: +31 (0) 20 204 6Slovensk republika Seqirus Netherlands B.V. Holandsko Tel: +31 (0) 20 204 6Suomi/Finland Seqirus Netherlands B.V. Alankomaat Puh/Tel: +31 (0) 20 204 6Sverige Seqirus Netherlands B.V. Nederl nderna Tel: +31 (0) 20 204 6Latvija Seqirus Netherlands B.V. N derlande Tel: +31 (0) 20 204 6This leaflet was last revised in {MM/YYYY}.
Other sources of information
Detailed information on this medicine is available on the European Medicines Agency web site:
Entry 1 - fullUrl = Composition/composition-en-2551c286e23d3921dbfab879452cee74
Resource Composition:
Generated Narrative: Composition composition-en-2551c286e23d3921dbfab879452cee74
Language: en
Profile: Composition (ePI)
identifier:
http://ema.europa.eu/identifier
/EU/1/20/1433/001status: Final
type: Package Leaflet
category: Raw
date: 2022-02-16 13:28:17+0000
author: Organization ACME industry
title: TEST PURPOSES ONLY - fluad
Attesters
Mode Time Official 2022-02-16 13:28:17+0000
Entry 2 - fullUrl = MedicinalProductDefinition/mp2551c286e23d3921dbfab879452cee74
Resource MedicinalProductDefinition:
Generated Narrative: MedicinalProductDefinition mp2551c286e23d3921dbfab879452cee74
identifier:
http://ema.europa.eu/identifier
/EU/1/20/1433/001type: Medicinal Product
domain: Human use
status: active
legalStatusOfSupply: Medicinal product subject to medical prescription
name
productName: Fluad Tetra, suspension for injection in pre-filled syringe
type: Full name
part
part: nan
type: Invented name part
part
part: nan
type: Scientific name part
part
part: nan
type: Strength part
part
part: nan
type: Pharmaceutical dose form part
Usages
Country Jurisdiction Language EU EU en